GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Five things you need to know, plus the big game and favorite commercials
Here are today's Five Things You Need to Know, plus a look at numbers from the big game and my favorite commercial. Good morning, Boston. Did you stay up for the whole game last night? (I didn’t.) ...
Zacks.com on MSN8d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...